RP — Replicel Life Sciences Balance Sheet
0.000.00%
- CA$0.74m
- CA$1.19m
- CA$0.35m
- 12
- 63
- 16
- 20
Annual balance sheet for Replicel Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 0.053 | 0.052 | 0.238 | 0.43 | 0.076 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.052 | 0.064 | 0.061 | 0.082 | 0.038 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.233 | 0.186 | 0.393 | 0.636 | 0.162 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.006 | 0.004 | 0.003 | 0.002 | 0.001 |
| Long Term Notes Receivable | |||||
| Total Assets | 0.505 | 0.421 | 0.592 | 0.798 | 0.288 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.27 | 2.24 | 1.67 | 2.07 | 1.82 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.93 | 5.48 | 7.43 | 6.71 | 4.82 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -4.43 | -5.06 | -6.84 | -5.92 | -4.53 |
| Total Liabilities & Shareholders' Equity | 0.505 | 0.421 | 0.592 | 0.798 | 0.288 |
| Total Common Shares Outstanding |